Amitabha Bhaumik

690 total citations
47 papers, 478 citations indexed

About

Amitabha Bhaumik is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Cancer Research. According to data from OpenAlex, Amitabha Bhaumik has authored 47 papers receiving a total of 478 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Pulmonary and Respiratory Medicine, 20 papers in Radiology, Nuclear Medicine and Imaging and 11 papers in Cancer Research. Recurrent topics in Amitabha Bhaumik's work include Prostate Cancer Treatment and Research (35 papers), Radiopharmaceutical Chemistry and Applications (19 papers) and Cancer, Lipids, and Metabolism (9 papers). Amitabha Bhaumik is often cited by papers focused on Prostate Cancer Treatment and Research (35 papers), Radiopharmaceutical Chemistry and Applications (19 papers) and Cancer, Lipids, and Metabolism (9 papers). Amitabha Bhaumik collaborates with scholars based in United States, Germany and United Kingdom. Amitabha Bhaumik's co-authors include Pablo Lapuerta, Stanley S. Franklin, Agata Ptaszynska, Joel M. Neutel, Suneel Mundle, Suzanne Oparil, Anil Londhe, Simon Chowdhury, David P. Greenberg and Corwin A. Robertson and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Kidney International.

In The Last Decade

Amitabha Bhaumik

39 papers receiving 465 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amitabha Bhaumik United States 11 221 156 139 99 88 47 478
Yoshio Taketani Japan 14 100 0.5× 316 2.0× 44 0.3× 90 0.9× 47 0.5× 34 573
Ganwei Shi China 11 130 0.6× 170 1.1× 131 0.9× 35 0.4× 27 0.3× 26 448
Ji Eun Heo South Korea 10 164 0.7× 104 0.7× 31 0.2× 25 0.3× 39 0.4× 39 436
Carlo Giammarresi Italy 11 63 0.3× 318 2.0× 86 0.6× 31 0.3× 48 0.5× 26 661
Yanmin Yang China 15 150 0.7× 302 1.9× 57 0.4× 30 0.3× 16 0.2× 41 572
Hisham Nassar Israel 14 223 1.0× 235 1.5× 57 0.4× 141 1.4× 25 0.3× 33 658
Yared Gurmu United States 13 78 0.4× 309 2.0× 177 1.3× 24 0.2× 29 0.3× 17 706
Hyun Hee Lee South Korea 15 72 0.3× 76 0.5× 50 0.4× 11 0.1× 106 1.2× 43 603
Boris Starčević Croatia 11 66 0.3× 141 0.9× 27 0.2× 59 0.6× 16 0.2× 46 383
Xiao‐Xiong Lin China 12 84 0.4× 367 2.4× 14 0.1× 88 0.9× 69 0.8× 14 640

Countries citing papers authored by Amitabha Bhaumik

Since Specialization
Citations

This map shows the geographic impact of Amitabha Bhaumik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amitabha Bhaumik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amitabha Bhaumik more than expected).

Fields of papers citing papers by Amitabha Bhaumik

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amitabha Bhaumik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amitabha Bhaumik. The network helps show where Amitabha Bhaumik may publish in the future.

Co-authorship network of co-authors of Amitabha Bhaumik

This figure shows the co-authorship network connecting the top 25 collaborators of Amitabha Bhaumik. A scholar is included among the top collaborators of Amitabha Bhaumik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amitabha Bhaumik. Amitabha Bhaumik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Borque‐Fernando, Ángel, Álvaro Juárez Soto, Cristian Vidal-Silva, et al.. (2025). Apalutamide in Patients with High Burden of Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of TITAN. European Urology Oncology. 8(5). 1311–1320.
3.
Shore, Neal D., Jason Hafron, Daniel R. Saltzstein, et al.. (2024). Apalutamide for High-Risk Localized Prostate Cancer Following Radical Prostatectomy (Apa-RP). The Journal of Urology. 212(5). 682–691. 2 indexed citations
4.
Shore, Neal D., Jason Hafron, Daniel R. Saltzstein, et al.. (2024). Impact of a rash management guide on incidence and severity of rash with apalutamide: Experience from the Apa-RP study in high-risk localized prostate cancer.. Journal of Clinical Oncology. 42(4_suppl). 316–316. 1 indexed citations
5.
Merseburger, Axel S., Anders Bjartell, Hirotsugu Uemura, et al.. (2024). Targeted Investigational Treatment Analysis of Novel Anti‐androgen (TITAN) study: ultralow prostate‐specific antigen decline with apalutamide plus androgen‐deprivation therapy. British Journal of Urology. 134(6). 982–991. 8 indexed citations
6.
Ye, Dingwei, Hirotsugu Uemura, Byung Ha Chung, et al.. (2024). Prostate‐specific antigen kinetics in Asian patients with metastatic castration‐sensitive prostate cancer treated with apalutamide in the TITAN trial: A post hoc analysis. International Journal of Urology. 32(2). 164–172. 2 indexed citations
7.
Chung, Byung Ha, Jian Huang, Hiroji Uemura, et al.. (2023). Apalutamide for metastatic castration-sensitive prostate cancer: final analysis of the Asian subpopulation in the TITAN trial. Asian Journal of Andrology. 25(6). 653–661. 3 indexed citations
8.
9.
Merseburger, Axel S., Neeraj Agarwal, Amitabha Bhaumik, et al.. (2023). Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study. European Journal of Cancer. 193. 113290–113290. 14 indexed citations
10.
Small, Eric J., Kim N., Simon Chowdhury, et al.. (2023). Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer. European Urology Oncology. 7(4). 844–852. 8 indexed citations
11.
12.
Shen, John, Simon Chowdhury, Neeraj Agarwal, et al.. (2023). Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN. British Journal of Cancer. 130(1). 73–81. 8 indexed citations
13.
Brown, Gordon, Laurence Belkoff, Jason Hafron, et al.. (2023). Maintenance of castration with concomitant relugolix and apalutamide (Apa) in patients with high-risk localized prostate cancer (HR-LPC): 1 year update.. Journal of Clinical Oncology. 41(16_suppl). e17094–e17094. 1 indexed citations
14.
Saad, Fred, Eric J. Small, Felix Y. Feng, et al.. (2021). Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN. European Urology. 81(2). 184–192. 35 indexed citations
15.
Bjartell, Anders, Neeraj Agarwal, Lawrence I. Karsh, et al.. (2021). MP24-08 RELATIONSHIPS OF SITES AND BURDEN OF METASTASES WITH LONG-TERM OUTCOMES AND MOLECULAR SUBTYPES IN TITAN. The Journal of Urology. 206(Supplement 3).
16.
Smith, Matthew R., Fred Saad, Simon Chowdhury, et al.. (2019). Predictors of falls and fractures in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with apalutamide (APA) plus ongoing androgen deprivation therapy (ADT).. Journal of Clinical Oncology. 37(15_suppl). 5025–5025. 13 indexed citations
17.
Mainwaring, Paul N., Eric J. Small, Hiroji Uemura, et al.. (2018). Efficacy and safety of apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from SPARTAN: Asian subpopulation. Annals of Oncology. 29. ix68–ix68. 4 indexed citations
18.
Parhofer, Klaus G., Kåre I. Birkeland, Ralph A. DeFronzo, et al.. (2009). Irbesartan has no short-term effect on insulin resistance in hypertensive patients with additional cardiometabolic risk factors (i-RESPOND). International Journal of Clinical Practice. 64(2). 160–168. 7 indexed citations
19.
NEUTEL, J, Stanley S. Franklin, Pablo Lapuerta, Amitabha Bhaumik, & Agata Ptaszynska. (2007). A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension. Journal of Human Hypertension. 22(4). 266–274. 28 indexed citations
20.
Neutel, Joel M., Stanley S. Franklin, Suzanne Oparil, et al.. (2006). Efficacy and Safety of Irbesartan/HCTZ Combination Therapy As Initial Treatment for Rapid Control of Severe Hypertension. Journal of Clinical Hypertension. 8(12). 850–859. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yoshio Taketani Breakdown of academic impact, for papers by Ganwei Shi Breakdown of academic impact, for papers by Ji Eun Heo Breakdown of academic impact, for papers by Carlo Giammarresi Breakdown of academic impact, for papers by Yanmin Yang Breakdown of academic impact, for papers by Hisham Nassar Breakdown of academic impact, for papers by Yared Gurmu Breakdown of academic impact, for papers by Hyun Hee Lee Breakdown of academic impact, for papers by Boris Starčević Breakdown of academic impact, for papers by Xiao‐Xiong Lin
Rankless by CCL
2026